Astellas Pharma Inc: Anemia trials

The registry lists 13 Anemia studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 1Phase 2 1Phase 3 10No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable DialysisCompletedNCT02278341Phase 3Results posted
• Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin AlfaCompletedNCT02021318Phase 3Results posted
• Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring DialysisCompletedNCT01887600Phase 3Results posted
• A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney DiseaseActive, not recruitingNCT05970172Phase 3
• A Non-interventional, Epidemiological, Registry-based Evaluation of Anaemia in Swedish Patients With Chronic Kidney DiseaseCompletedNCT03643601
• A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With AnemiaCompletedNCT02988973Phase 3
• A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With AnemiaCompletedNCT02964936Phase 3
• A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With AnemiaCompletedNCT02952092Phase 3
• A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With AnemiaCompletedNCT02780726Phase 3
• A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With AnemiaCompletedNCT02780141Phase 3
• A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) TreatmentCompletedNCT02779764Phase 3
• ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-CompletedNCT01964196Phase 2
• ASP1517 Pharmacokinetics Study in Anemia Patients on HemodialysisCompletedNCT01083888Phase 1